NCT06687928View on ClinicalTrials.gov

To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

August 5, 2025

Study Completion Date

August 5, 2025

Conditions
Healthy
Interventions
BIOLOGICAL

CT-P6 SC

A single fixed dose (600 mg) of CT-P6 subcutaneous

BIOLOGICAL

EU-Approved Herceptin SC

A single fixed dose (600 mg) of EU-approved Herceptin subcutaneous

Trial Locations (1)

22006

Celltrion, Yeonsu-gu

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY